Definition of the clinical rationale of pembrolizumab administration in these patients and whether MMR testing by IHC can be employed as a biomarker of prognosis and chemotherapy efficacy require validation in independent cohorts of breast cancer patients. Here, MRC1 is linked to breast carcinoma.